Views & Analysis JPM: Four ways FDA is seeking to buoy gene therapy On the outskirts of the JP Morgan Healthcare Conference today, FDA's Dr Peter Marks discussed how to get more gene therapies approved in 2024.
News Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt Alphabet’s artificial intelligence start-up Isomorphic Labs has made a splash at the start of the JP Morgan Healthcare conference this week, announcing its first pharma pa
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.